Jan 13 (Reuters) - U.S. based-Regeneron Pharmaceuticals Inc and Germany's Bayer AG said they would co-develop an antibody for use in combination with Eylea, their treatment for a form of age ...

The HealthCare segment at Bayer (BAYRY) announced that it has submitted a Marketing Authorisation Application for Eylea (aflibercept solution) for the treatment of patients suffering from visual ...

Bayer A.G. ( OTCPK:BAYZF) ( OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the ...

May 23, 2025 Bayer wins EU watchdog's endorsement for longer Eylea treatment intervals German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals ...

On the surface, macular degeneration treatment Eylea continued its juggernaut path in 2022. On Tuesday, when Bayer reported fourth quarter earnings, it showed 3.2 billion euros ($3.4 billion ...

FRANKFURT, Sept 8 (Reuters) - Bayer (BAYGn.DE), opens new tabsaid on Thursday its anti-blindness treatment Eylea, jointly developed with Regeneron (REGN.O), opens new tab, has been shown to work ...

2014 – Bayer HealthCare has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for EYLEA® (aflibercept solution for injection) for the treatment of myopic ...

Bayer HealthCare's Eylea (aflibercept solution for injection into the eye) has been approved by the European Commission for the treatment of visual impairment due to diabetic macular oedema (DMO).

Bayer has licensed exclusive marketing rights outside the United States, where the companies share equal profits from the sales of Eylea. Eylea’s intravitreal injection 40 mg/mL has been approved for ...

Eylea HD is a higher dose of an existing drug, aflibercept, that’s already used to treat wet macular degeneration and diabetic macular edema. Americans diagnosed with wet age-related macular ...